Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349646 | 0.89 | KMT2A (0.55) | ELANEKMT2AKDM4EALDH1A1ACHE | |
| SCHEMBL5356842 | 0.85 | KDM4E (0.49) | KMT2AL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL5356625 | 0.84 | KMT2A (0.45) | ELANEKMT2AL3MBTL1BCHEHPGD | |
| SCHEMBL8482779 | 0.75 | HTR6 (0.54) | ELANEKMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5354006 | 0.72 | KMT2A (0.55) | KMT2AKDM4EALDH1A1ACHETHRB | |
| SCHEMBL14450976 | 0.70 | ALDH1A1 (0.51) | KMT2AL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL2549273 | 0.68 | PIK3CG (0.58) | KMT2AL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL5358132 | 0.67 | DYRK1A (0.47) | KMT2AL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL5357533 | 0.67 | KMT2A (0.56) | ELANEKMT2AKDM4EALDH1A1BCHE | |
| SCHEMBL7836476 | 0.67 | L3MBTL1 (0.55) | KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176230-B2 | Synthesis of indole analogs of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl) indazole (YC-1) as anti-platelet agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2007-02-13 | — | — | US | disclosed |
| US-20060106041-A1 | Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106041-A1 | Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents | PFKP, HMOX1, TPH1 | ELANE 2497/4885KMT2A 2910/4885L3MBTL1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.